Stuttgart - Delayed Quote ? EUR Gritstone bio, Inc. (2JQ.SG) Follow Compare 0.0294 0.0000 (0.00%) At close: October 21 at 9:31 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Gritstone Oncology Pursues Restructuring Through Chapter 11 Gritstone Oncology ( (GRTS) ) has shared an update. Gritstone bio, Inc., a biotech firm specializing in potent vaccines, has voluntarily filed for Chapter 11 bankruptcy to restructure and preserve its value while continuing operations. This move is part of a strategic process to explore alternatives and secure a stalking horse bidder to maximize value, demonstrating commitment to advancing clinical programs. Despite the filing, the company aims to maintain normal operations and minimize impact o TipRanks ? 16 days ago GRTS Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure EMERYVILLE, Calif., October 10, 2024--Gritstone bio, Inc. (Nasdaq: GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Business Wire ? 17 days ago GRTS Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific GlobeNewswire ? 26 days ago GRTS Gritstone bio Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag Gritstone bio ( NASDAQ:GRTS ) Second Quarter 2024 Results Key Financial Results Revenue: US$921.0k (down 53% from 2Q... Simply Wall St. ? 2 months ago GRTS Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the b GlobeNewswire ? 2 months ago GRTS Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) -- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it will host a virtual key opinion leader (KOL) event on Friday, August 2 at 9:00 AM ET featuring J. Randolph Hecht, MD, (Professor, UCLA Gastrointestinal Oncology GlobeNewswire ? 3 months ago GRTS Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 39,000 shares of its common stock with an exercise price of $0.57, which is equal to the closing price of Gritstone’s common stock on July 3, 2024, the date GlobeNewswire ? 3 months ago GRTS Gritstone bio to Participate in Upcoming Investor and Scientific Conferences EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: Goldman Sachs 45th Annual Global Healthcare Conference (Fireside Chat*)Date and Time: Tuesday, June 11, 2024 at 1:20pm ETLocation: Miami, FL JonesHealthcare Seaside Summit 2024 (1x1s)Dates: Monday, July 15 - Tu GlobeNewswire ? 4 months ago GRTS Gritstone bio First Quarter 2024 Earnings: Misses Expectations Gritstone bio ( NASDAQ:GRTS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.74m (down 29% from 1Q... Simply Wall St. ? 5 months ago GRTS Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates -- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 -- -- Nature Medicine publication of Phase 1 study of SLATE (off-the-shelf neoantigen vaccine) and AACR-presented improvements to EDGE? (tumor antigen identification platform that was recently enhanced GlobeNewswire ? 5 months ago GRTS Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024 -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To acce GlobeNewswire ? 5 months ago GRTS Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024 -- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of any of the samRNA constructs -- -- Comprehensive data set demonstrates a consistent and strong immunogenicity profile across multiple patient populations in South Africa, including people living with HIV -- EMERYVI GlobeNewswire ? 5 months ago GRTS Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The GlobeNewswire ? 5 months ago GRTS Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE) -- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) -- -- Publication underscores the important role of antigen selection and cassette design in the development of neoan GlobeNewswire ? 6 months ago GRTS Gritstone bio Presents Improvements to EDGE? Platform at AACR 2024 -- State-of-the-art neoantigen prediction platform (EDGE?) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILL GlobeNewswire ? 6 months ago GRTS Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deductin GlobeNewswire ? 6 months ago GRTS Gritstone bio Announces Proposed Public Offering EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares of commo GlobeNewswire ? 6 months ago GRTS Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) -- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases -- -- Short-term molecular response (as defined by protocol) is uninformative due to an unexpectedly persi GlobeNewswire ? 6 months ago GRTS 3 Speculative Stocks You Can Buy for $3 or Less The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars aligning perfectly, which rarely happens. Still, analyst-endorsed ideas could put the odds in the gamblers’ favor. Another reason why speculative stocks are so enticing is accessibility. Not all brokerages offer fractional ownership of shares. Therefore, some retail investors may be blocked out of in InvestorPlace ? 7 months ago GRTS Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates Gritstone bio, Inc. ( NASDAQ:GRTS ) just released its latest yearly results and things are looking bullish. Overall... Simply Wall St. ? 7 months ago GRTS Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return 2JQ.SG S&P 500 YTD -98.39% +21.77% 1-Year -98.39% +36.74% 3-Year -99.60% +27.79%
